中文
ABOUT
Overview
Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.
Board of Directors
Dr. Ma Zhenkun
Chairman of the Board, Executive Director, Chief Executive Officer and General Manager
Dr. Song Gaoguang
Non-executive Director
Mr. Michael James Bakes
Non-executive Director
Dr. Martin Friedrich Heidecker
Non-executive Director
Mr. Lee Wai Kong
Independent Non-executive Director
Dr. Ni Lin
Independent Non-executive Director
Dr. Li Leping
Independent Non-executive Director
Scientific Advisory Board
Dr. Xiaodong WANG
Member of the U.S. National Academy of Sciences and the Chinese Academy of Sciences; head of China’s National Institute of Biological Sciences
Dr. Richard Losick
Member of the U.S. National Academy of Sciences, the American Association for the Advancement of Science and the American Academy of Arts and Sciences; Professor, Department of Molecular and Cellular Biology, Harvard University
Dr. Steven McKnight
Member of the U.S. National Academy of Sciences, the U.S. Institute of Medicine and the American Academy of Arts and Sciences；Professor, Biochemistry Department, University of Texas Southwestern Medical Center
Dr. Kenneth Chang
An internationally recognized leader in gastroenterology; Professor and Chief, Division of Gastroenterology and Executive Director of the H. H. Chao Comprehensive Digestive Disease Center, School of Medicine, University of California, Irvine
Team
Dr. Ma Zhenkun
Chairman of the Board, Executive Director, Chief Executive Officer and General Manager
Dr. Bi Jie
Chief Business Officer
Dr. Geng Guozhu
VP, Medical Affairs
Ms. Chen Jing
VP, Clinical Operations
Ms. Yu Yinjiao
Senior Vice President of Regulatory Affairs
Ms. Chen Rongping
Vice President of Finance and Board Secretary
MILESTONES
2016
TNP-2092 Capsules received IND from NMPA
2018
Rifaquizinone IV received IND from FDA and initiated Phase II clinical trial for ABSSSI in the United States
Rifasutenizol received IND from NMPA for the treatment of H. pylori infection, BV, and Clostridium difficile infection
2019
Rifaquizinone IV was granted QIDP designation by FDA for ABSSSI, CRBSI, and PJI
Completed Rifaquizinone IV Phase II clinical trial for ABSSSI in the United States with positive results
2020
Initiated TNP-2092 Capsule Phase II clinical trial for hyperammonemia in liver cirrhosis patients
Rifaquizinone IV was granted Orphan Drug designation by FDA for PJI
Initiated Rifasutenizol Phase II clinical trial for H. pylori infection
Shortlisted as a Suzhou Unicorn Cultivation Enterprise
2021
Completed TNP-2092 Capsule Phase II clinical trial for hyperammonemia in liver cirrhosis patients with positive results
2022
Completed Rifasutenizol Phase II clinical trial for the treatment of H. pylori infection with positive results
TNP-2092 IV for medical device infection won the Outstanding Award at the National Disruptive Technology Innovation Competition (全國顛覆性技術創新大賽)
2023
Rifasutenizol for H. pylori infection received IND from FDA
Rifasutenizol was granted QIDP and Fast Track designations by FDA
Initiated Rifasutenizol Phase III clinical trial
TNP-2092 IA received IND from NMPA for PJI
TNP-2092 Ointment received IND from NMPA for the DFI
2024
Completed Phase III clinical trial of Rifasutenizol for H. pylori infection, meeting the primary endpoint
Signed partnership agreement with Grand Life Science for commercialization of Rifasutenizol
2025
Initiated Rifaquizinone IA Phase II clinical trial for PJI
Obtained Class B Pharmaceutical Manufacturing License (藥品生產許可B證) for Rifasutenizol
Rifasutenizol received NDA from NMPA for the treatment of H. pylori infection
